A Phase 1/2 interventional study of ST-400 Investigational product in Transfusion Dependent Beta-thalassemia, sponsored by Sangamo Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Sangamo Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.
Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 64th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is one of 11 in phase 1/2, and was the 52nd registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
Daniel Bauer · Sites in United States
Ages 13–40
xCures · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 41 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 25 across the 71 interventional studies, 150 across the 17 observational. Of the 50 that completed or were terminated, 17 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 91 have an industry lead sponsor. The 10 most frequent:
Sangamo Therapeutics is the lead sponsor of 28 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Sangamo Therapeutics has 2 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
11 of the studies in beta-Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in beta-Thalassemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age. ST-400 is a type of investigational therapy that consists of gene edited cells. ST-400 is composed of the patient's own blood stem cells which are genetically modified in the laboratory using Sangamo's zinc finger nuclease (ZFN) technology to disrupt a precise and specific sequence of the enhancer of the BCL11A gene (which normally suppresses fetal hemoglobin production in erythrocytes). This process is intended to boost fetal hemoglobin (HbF), which can substitute for reduced or absent adult (defective) hemoglobin. ST-400 is then infused back into the patient after receiving conditioning chemotherapy to make room for the new cells in the bone marrow, with the aim of producing new erythrocytes with increased amounts of HbF. The primary objective is to understand safety and tolerability of ST-400, and secondary objectives are to assess the effects on HbF levels and transfusion requirements.
Once consented, study participants will progress through the following stages:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
Genetic: ST-400 Investigational product
Single dose of ST-400 following chemotherapy conditioning with busulfan
Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion
Safety and tolerability assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 weeks after the ST-400 infusion
Time frame: Up to 156 weeks after the ST-400 infusion
Clinical Laboratory Measurement of Hemoglobin (Hb) Fractions (A and F in g/dL)
Change from baseline clinical laboratory measurement of Hb fractions (A and F in g/dL) \[Time Frame: Up to 156 weeks after ST-400 infusion\]
Time frame: Baseline, Weeks 26, 52, and 156 after ST-400 infusion
Clinical Laboratory Measurements of Percent (%) HbF
Change from baseline percent (%) HbF \[Time Frame: Up to 156 weeks after ST-400 infusion\]
Time frame: Baseline, Weeks 26, 52, and 156 after ST-400 infusion
Annualized Frequency of Packed RBC Transfusions
Calculation of annualized frequency and volume of packed red blood cell (PRBC) transfusions after ST-400 infusion transfusion support in the 2 years prior to screening
Time frame: From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)
Annualized Volume (mL) of Packed RBC Transfusions
Historical baseline defined as transfusion support in the 2 years prior to screening.
Time frame: From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)
The original enrollment goal was six subjects were to be enrolled in the Phase 1/2 study ST-400-01, but 5 subjects were enrolled and dosed. One subject from the 5 dosed withdrew consent prior to completing the study. Subjects who received treatment with ST-400 were asked to participate in a separate observational long-term safety study.
| Milestone | ST-400 Investigational Product |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
| Milestone | ST-400 Investigational Product |
|---|---|
| Started | 5 |
| Completed | 4 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Safety and tolerability assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 weeks after the ST-400 infusion
| participants | ST-400 Investigational Product |
|---|---|
| Incidence of non-serious adverse events | 5 |
| Incidence of serious adverse events | 2 |
Change from baseline clinical laboratory measurement of Hb fractions (A and F in g/dL) \[Time Frame: Up to 156 weeks after ST-400 infusion\]
| g/dL | ST-400 Investigational Product |
|---|---|
| Hemoglobin A (g/dL) Change from Baseline to Week 26 | -3.648 ± 2.0401 |
| Hemoglobin A (g/dL) Change from Baseline to Week 52 | -3.227 ± 2.0789 |
| Hemoglobin A (g/dL) Change from Baseline to Week 156 | -0.281 ± 1.5834 |
| Hemoglobin F (g/dL) Change from Baseline to Week 26 | 1.025 ± 1.0898 |
| Hemoglobin F (g/dL) Change from Baseline to Week 52 | 0.405 ± 0.2851 |
| Hemoglobin F (g/dL) Change from Baseline to Week 156 | 0.502 ± 0.2936 |
Change from baseline percent (%) HbF \[Time Frame: Up to 156 weeks after ST-400 infusion\]
| Percentage of Hemoglobin F | ST-400 Investigational Product |
|---|---|
| Week 26 | 12.83 ± 14.282 |
| Week 52 | 5.30 ± 3.188 |
| Week 156 | 4.35 ± 3.040 |
Calculation of annualized frequency and volume of packed red blood cell (PRBC) transfusions after ST-400 infusion transfusion support in the 2 years prior to screening
| PRBC transfusions/year | ST-400 Investigational Product |
|---|---|
| Baseline transfusion support 2 years prior to screening/consent | 17.393 ± 5.4350 |
| At ST-400 Infusion (Day 0) | 21.518 ± 4.8806 |
| After hematopoietic reconstitution (up to 156 weeks after ST-400 infusion) | 19.665 ± 5.6716 |
Historical baseline defined as transfusion support in the 2 years prior to screening.
| mL/year | ST-400 Investigational Product |
|---|---|
| Baseline transfusion support 2 years prior to screening/consent | 10295.984 ± 4063.3661 |
| At ST-400 infusion (Day 0) | 7453.191 ± 4204.3456 |
| After hematopoietic reconstitution (up to 156 weeks after ST-400 infusion) | 7068.788 ± 4480.8901 |
Collected over Participants with adverse events data collected from ICF signed through participant's last study visit, up to 156 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ST-400 Investigational Product | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Event | ST-400 Investigational Product |
|---|---|
| Drug withdrawal syndromeGeneral disorders | 1/5 |
| HypersensitivityImmune system disorders | 1/5 |
| PneumoniaInfections and infestations | 1/5 |
| Event | ST-400 Investigational Product |
|---|---|
| NauseaGastrointestinal disorders | 5/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/5 |
| InsomniaPsychiatric disorders | 5/5 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/5 |
| AnaemiaBlood and lymphatic system disorders | 4/5 |
| ConstipationGastrointestinal disorders | 4/5 |
| StomatitisGastrointestinal disorders | 4/5 |
| NeutropeniaBlood and lymphatic system disorders | 3/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/5 |
| DiarrhoeaGastrointestinal disorders | 3/5 |
The study population comprise male and non-pregnant, non-lactating female subjects with TDT between 18 and 40 years old, who are willing and able to undergo autologous HSCT.
| Age, Continuous(years) | ST-400 Investigational Product |
|---|---|
| Mean | 28.4 ± 7.77 |
| Sex: Female, Male(Participants) | ST-400 Investigational Product |
|---|---|
| Sex — Female | 2 |
| Sex — Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | ST-400 Investigational Product |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ST-400 Investigational Product |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | ST-400 Investigational Product |
|---|---|
| United States | 5 |
| Hemoglobin A (g/dL) at Baseline(g/dL) | ST-400 Investigational Product |
|---|---|
| Mean | 11.040 ± 0.6006 |
| Hemoglobin F (g/dL) at Baseline(g/dL) | ST-400 Investigational Product |
|---|---|
| Mean | 0.169 ± 0.0835 |
| Hemoglobin F Percentage at Baseline(Percentage) | ST-400 Investigational Product |
|---|---|
| Mean | 1.48 ± 0.760 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Nov 2022, 55 months.
Results were first posted in Dec 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.